Basiliximab induction therapy in kidney transplantation: Benefits for long term allograft function after 10 years?

Biologics: Targets and Therapy

Volumn 3, Issue , 2009, Pages 51-56

  Koch, Martina ^a   Becker, Thomas ^a   Lueck, Rainer ^a   Neipp, Michael ^a   Klempnauer, Juergen ^a   Nashan, Bjoern ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Basiliximab; Induction therapy; Long term graft survival; Renal transplantation

Indexed keywords

EID: 65349173007     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: 10.2147/BTT.S4437     Document Type: Article

References (17)

1. Amlot PL, Rawlings E, Fernando ON, et al. Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation. Transplantation. 1995; 60:748-756.
2. Kahan BD, Rajagopalan PR, Hall M. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group. Transplantation. 1999;67:276-284.
3. Nashan B, Moore R, Amlot P, Schmidt AG, Abeywickrama K, Soulillou JP. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. Lancet. 1997;350:1193-1198.
4. Vincenti F, de Andres A, Becker T, et al. Interleukin-2 receptor antagonist induction in modern immunosuppression regimens for renal transplant recipients. Transplant Int. 2006;19:446-457.
5. Matas AJ, Gilligham KJ, Payne WD, Najarian JS. The impact of an acute rejection episodes on long-term renal allograft survival (t1/2). Transplantation. 1994;57:857-859.
6. Tesi RJ, Henry ML, Elkhammas EA, Furguson RM. Predictors of long-term primary cadaveric renal transplant survival. Clin Transplant. 1993;7:345-352.
7. Furguson R. Acute rejection episodes: best predictor of long-term primary cadaveric renal transplant survival. Clin Transplant. 1994;8:328-331.
8. Hibberd AD, Trevillian JH, Wlodarzcyk JH, et al. Cancer risk associated with ATG/OKT3 in renal transplantation. Transplant Proc. 1999;31:1271-1272.
9. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Eng J Med. 1990;323:1723-1728.
10. Webster AC, Playford EG, Higgins G, Chapman JR, Craig JC. Interleukin 2 receptor antagonists for renal transplant recipients: a metaanalysis of randomized trials. Transplantation. 2004;77:166-176.
11. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
12. Wabbijn M, Balk AH, van Dormburg RT, et al. Ten-year follow-up of recipients of a kidney or heart transplant who received induction therapy with a monoclonal antibody against the interleukin-2 receptor. Exp Clin Transplant. 2004;2:201-207.
13. Beaudreuil S, Durrbach A, Noury J, et al. Long-term results (10 years) of a prospektice trial comparing Lo-tact-1 monoclonal antibody and anti-thymocyte globulin induction therpy in kidney transplantation. Transplant Int. 2006;19:814-820.
14. Kyllönen LE, Eklund BH, Pesonen EJ, Samela KT. Single bolus antitymocyte globulin versus basiliximab induction in kidney transplantation with cyclosporine tripple immunosuppression: efficacy and safety. Transplantation. 2007;84:75-82
15. Chapman JR, Webster AC. Cancer after renal transplantation: The next challenge. Am J Transplant. 2004;4:841-842.
16. Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am J Transplant. 2004;4:905-913.
17. Kessler M, Jay N, Molle R, Guillemin F. Excess risk of cancer in renal transplant patients. Transplant Int. 2006;19:908-914.